Synchron secures nitinol electrode supply

This stake shows that Synchron is not treating the electrode as an off the shelf part, it is treating it as the core manufacturing bottleneck behind its whole endovascular strategy. The Stentrode depends on an ultra thin nitinol structure that must expand inside a blood vessel, sit safely against the vessel wall, and still carry recording contacts, so owning part of the supplier helps lock in a specialized process that few device makers can easily replicate or swap out.

• Acquandas specializes in sputtered and micro patterned nitinol and other metallic micro components for medical devices. That matters because Synchron is not buying generic catheter parts, it needs a custom stent like electrode array that combines stent mechanics with neural sensing.
  3 cnbc 4 acquandas
• Synchron competes against players like Neuralink that are more vertically integrated around chips, electrodes, and surgical systems. For Synchron, taking an equity position in a fabrication partner is a lighter version of the same play, securing a hard to copy component without building the factory from scratch.
  2 sacra 5 synchron 6 medicaldevicenetwork
• The supply chain angle is also about product roadmap, not just procurement. Synchron ties the Acquandas relationship to future sensing plus stimulation devices, which would move the company from assistive communication into neuromodulation markets like depression, pain, and epilepsy.
  1 sacra 2 sacra

Going forward, the winners in BCI will be the ones that control the hardest manufacturing steps, not just the decoding software. If Synchron keeps pairing a catheter lab friendly procedure with proprietary electrode supply, it can defend its minimally invasive niche and extend that platform into higher value therapeutic implants.